Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr 8;7:6.
doi: 10.1186/1476-5918-7-6.

The Economic Impact of ME/CFS: Individual and Societal Costs

Free PMC article

The Economic Impact of ME/CFS: Individual and Societal Costs

Leonard A Jason et al. Dyn Med. .
Free PMC article


Background: ME/CFS is characterized by debilitating fatigue in addition to other physical and cognitive symptoms. It is estimated to affect over 800,000 adults in the U.S. ME/CFS often results in diminished functionality and increased economic impact. The economic impact of an illness is generally divided into two categories: direct and indirect costs. Despite high prevalence rates and the disabling nature of the illness, few studies have examined the costs of ME/CFS at the individual and societal level. In fact, of the four studies examining the economic impact of ME/ME/CFS only two used a U. S. sample. The current study used community and tertiary samples to examine the direct costs of ME/CFS.

Methods: Using archival data, Study 1 examined the direct cost of ME/CFS in a community-based sample in Chicago. Study 2 estimated the direct cost of ME/CFS in a tertiary sample in Chicago. Both Study 1 and Study 2 assessed direct costs using office visit costs, medical test costs, and medication costs.

Results: For Study 1, the annual direct total cost per ME/CFS patient was estimated to be $2,342, with the total annual direct cost of ME/CFS to society being approximately $2 billion. In Study 2, the annual direct was estimated to be $8,675 per ME/CFS patient, with the total annual direct cost of ME/CFS to society being approximately $7 billion.

Conclusion: Using ME/CFS prevalence data of 0.42 and indirect costs estimates from Reynolds et al. (2004), the direct and indirect cost of ME/CFS to society was estimated to be $18,677,912,000 for the community sample and $23,972,300,000 for the tertiary sample. These findings indicate that whether or not individuals are recruited from a community or tertiary sample, ME/CFS imposes substantial economic costs.

Similar articles

See all similar articles

Cited by 61 articles

See all "Cited by" articles


    1. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR. A community-based study of chronic fatigue syndrome. Archives of Internal Medicine. 1999;159:2129–2137. doi: 10.1001/archinte.159.18.2129. - DOI - PubMed
    1. Hill NF, Tiersky LA, Scavalla VR, Lavietes M, Natelson BH. Natural history of severe chronic fatigue syndrome. Journal of Archives of Physical Medicine and Rehabilitation. 1999;80:1090–1094. doi: 10.1016/S0003-9993(99)90066-7. - DOI - PubMed
    1. Reyes M, Dobbins JG, Nisenbaum R, Subedar NS, Randall B, Reeves WC. Chronic fatigue syndrome progression and self-defined recovery: evidence from the CDC surveillance system. Journal of Chronic Fatigue Syndrome. 1999;5:17–27.
    1. Jason LA, Fennell PA, Taylor RR, (Eds) The Handbook of chronic fatigue syndrome. New York: John Wiley & Sons, Inc; 2003.
    1. Bombardier CH, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia: Disability and health care use. Medical Care. 1996;34:924–930. doi: 10.1097/00005650-199609000-00005. - DOI - PubMed